Alzheimer’s Drug Discovery Foundation announced that the amyloid-clearing drug lecanemab will be a positive step in the treatment of Alzheimer’s disease based on study results presented at the 15New England Journal of Medicinetreatment, while combination therapy remains the holy grail.
. Lecanemab is poised for FDA approval early next year. Alzheimer’s is a complex disease with multiple underlying causes tied to the biology of aging, therefore the Alzheimer’s Drug Discovery Foundation has long held that a combination drug approach is needed. Amyloid-clearing drugs are one part of the solution, but there remains a pressing need to develop a new generation of drugs targeting all aspects of the biology of aging that can be combined to address the full array of underlying pathologies that contribute to the disease.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NatureMedicine - 🏆 451. / 53 Read more »